Gilead Announces Publication of PURPOSE 2 Results in New England Journal of Medicine
Gilead Sciences is a pharmaceutical company focused on researching and developing treatments for a variety of diseases, ranging from HIV and viral hepatitis to oncology and inflammation. Our commitment to research and development is central to our mission, as we strive to create innovative medicines that make a positive impact on patients’ lives.
In our efforts to advance medical knowledge and improve patient outcomes, we have various programs in place to support research funding. These programs include the Research Scholars Program and opportunities for external-sponsored research in areas such as virology, oncology, and inflammation. We also prioritize community-based participatory research to ensure that our work addresses the needs of diverse populations.
At Gilead Sciences, patient safety is a top priority. We are dedicated to combating counterfeiting and ensuring the safety of consumer products. Our commitment to medication access includes programs for U.S. patient access and managed access through authorized distributors.
In addition to our focus on research, we are actively involved in corporate giving and social responsibility initiatives. Through programs like All4Liver, the COMPASS Initiative, and the Gilead Oncology Grant, we seek to promote health equity and support vulnerable populations.
As part of our global health and access efforts, we are committed to expanding access to our medicines in low- and middle-income countries. Through partnerships and collaborations, we aim to address critical health challenges, such as invasive fungal infections.
Gilead Sciences values inclusion and diversity within our organization, with employee resource groups like GAIN, Gileados, and Pride Alliance fostering a culture of belonging and support. Our commitment to medical education and storytelling allows us to engage with healthcare providers and patients to enhance understanding and awareness of important health issues.
Our leadership team, including individuals like Daniel O’Day and Cindy Perettie, guides our work with expertise and dedication. The Gilead Sciences Board of Directors, led by Daniel O’Day and comprised of accomplished professionals like Jacqueline K. Barton and Kelly A. Kramer, provides strategic oversight and governance to ensure the company’s continued success.
Overall, Gilead Sciences is driven by a commitment to improving the lives of patients through innovative research, responsible corporate citizenship, and a dedication to health equity. We are proud to play a role in shaping the future of healthcare and look forward to continuing our mission of creating possible solutions for patients in need.
